These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36388025)

  • 1. Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic
    Zheng W; Niu N; Zeng J; Ke X; Jin S
    Transl Cancer Res; 2022 Oct; 11(10):3895-3902. PubMed ID: 36388025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
    Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
    Li X; Wang S; Li B; Wang Z; Shang S; Shao Y; Sun X; Wang L
    Target Oncol; 2018 Aug; 13(4):517-523. PubMed ID: 29907952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Deacetylase 3 Inhibition Overcomes
    Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
    Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
    [No Abstract]   [Full Text] [Related]  

  • 7. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
    Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
    Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib in uncommon
    Wang Y; Dorwal P; Rajadurai S; Arulananda S
    Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
    Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
    Front Oncol; 2021; 11():733276. PubMed ID: 34760695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
    Zhou Q; Li J; Cang SD; Lin JX; Tu HY; Du Y; Qin JW; Liang XH; Yu Y; Lan HT; Shi HQ; Hua D; Liu SM; Wu YL
    Clin Lung Cancer; 2024 Sep; ():. PubMed ID: 39424513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.
    Isobe K; Yoshizawa T; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Sakamoto S; Takai Y; Tomida T; Adachi-Akahane S; Iyoda A; Homma S; Kishi K
    Respir Investig; 2021 Jul; 59(4):535-544. PubMed ID: 33934994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.
    Zou Q; Zhan P; Lv T; Song Y
    Transl Lung Cancer Res; 2015 Dec; 4(6):792-6. PubMed ID: 26798589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
    Xia J; Bai H; Yan B; Li R; Shao M; Xiong L; Han B
    Oncotarget; 2017 Dec; 8(65):108522-108533. PubMed ID: 29312548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
    Shen Q; Qu J; Chen Z; Zhou J
    Front Oncol; 2021; 11():760097. PubMed ID: 34926262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.
    Chen J; Zhao X; Wang J; Liu F; Zhang L; Chen Y; Chu Q
    Transl Cancer Res; 2022 Sep; 11(9):3343-3348. PubMed ID: 36237272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.